VoorheesPMKaufmanJLLaubachJ, et al.Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood2020; 136: 936–945.
2.
MoreauPAttalMHulinC, et al.Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study [published correction appears in Lancet. 2019 Jun 14;:]. Lancet2019; 394: 29–38.
3.
FaconTKumarSKPlesnerT, et al.Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol2021; 22: 1582–1596.
4.
MateosMVDimopoulosMACavoM, et al.Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med2018; 378: 518–528.
5.
LonialSLeeHCBadrosA, et al.Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol2020; 21: 207–221.
6.
BazarbachiAHAl HamedRMalardF, et al.Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J2022; 12: 47.
7.
RousselMMoreauPHebraudB, et al.Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. Lancet Haematol2020; 7: e874–e883.
8.
San-MiguelJAvet-LoiseauHPaivaB, et al.Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood2022; 139: 492–501.
9.
DermanBAKansagraAZonderJ, et al.Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent: a phase 2 measurable residual disease-adapted study. JAMA Oncol2022; 8: 1278–1286.
10.
CornellRHariPTangS, et al.Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol2021; 96: E5–E8.
11.
YamamotoCMinakataDKoyamaS, et al.Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma. Blood2022; 140: 594–607.
12.
PeregoGLongobardoGVenezianoC, et al.Not only a time-saving approach: is it the time of subcutaneous formulation for daratumumab administration?J Oncol Pharm Pract2021; 27: 1751–1752.
13.
ClinicalTrials.gov Identifier: NCT05535244.
14.
ChariAMinnemaMCBerdejaJG, et al.Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med2022; 387: 2232–2244.
15.
LonialSPopatRHulinC, et al.Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol2022; 9: e822–e832.
